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Abstract A 69-year-old man under long-term spironolac-
tone therapy (16 years) was hospitalized with spontaneous
hematoma on the trunk and extremities. Coagulation stud-
ies disclosed an acquired hemophilia that was successfully
treated with human factor VIII for a few days and im-
munosuppressive agents for several months. Physical
examination revealed bilateral gynecomastia and an upper
left quadrant breast nodule. Complete staging was unre-
markable. Complete left mastectomy was performed. His-
topathology showed invasive ductal carcinoma, expressing
positivity for estrogen and progesterone receptors. The
acquired hemophilia was considered to be a paraneoplasic
syndrome. The question of a linkage between long-term
spironolactone therapy and breast carcinoma is discussed.
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Introduction
Acquired hemophilia is a rare disease, considered to be a
paraneoplasic syndrome in nearly 10% of cases.1 Male
breast carcinoma accounts for nearly 1% of all diagnosed
breast carcinomas.2,3 Unfortunately, male breast cancer is
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often diagnosed at a late stage because of the minimal
awareness of presenting symptoms by the patient and some-
times by the health-care provider. Because of this late
presentation, the overall prognosis is less favorable.2,3
Spironolactone has antiandrogenic characteristics, and
animal data suggest the oncogenic potential of spironolac-
tone’s metabolite. We report a very rare case of a man
under long-term spironolactone therapy who was hospital-
ized for hematoma as the first manifestation of an acquired
hemophilia related to breast carcinoma.
Case report
A 69-year-old man with a history of membranous nephro-
pathy and moderate renal failure (creatinine clearance,
50ml/min) had been on spironolactone therapy (100mg/
day) for 16 years. He was known to have atrial fibrillation,
hyperlipidemia, and diabetes. Co-medications included
furosemide, digoxin, acenocoumarol, simvastatin, and
glibenclamide. He was hospitalized on September 12, 2001
with arthralgia and spontaneous hematoma on the trunk
and extremities.
At presentation, his hemoglobin level was 88g/dl, white
cell count was 17000/µl, and platelet count was 36.4  104/
µl. Complete chemistry confirmed an elevated creatinine
level, at 120µmol/l (normal range, 44–106µmol/l) and re-
vealed only a slight increase of total creatine kinase and
lactate dehydrogenase. Urinanalysis was normal. Coagula-
tion studies disclosed: prothrombin time, 130% (normal
range, 85%–125%); activated partial thromboplastin time,
91 sec (normal range, 21–33 sec); fibrinogen, 5.8g/l (normal
range, 1.6–3.8g); negative fibrin monomer; D-dimer, 0.4–
0.8mg/l (normal range, 0.2mg). Factor VIII was very low,
at 1% (normal range, 70%–150%) and an inhibitor was
identifiable.
An acquired hemophilia was diagnosed. Fresh frozen
plasma was initiated upon presentation. Once factor VIII
inhibitor was discovered, human factor VIII was started, at
a dose of 200UI/kg per day. This treatment was given at a
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tapered dose, according to the clinical status and the nor-
malization of factor VIII values, for a period of 16 days.
Immunosuppressive agents, including cyclophosphamide
200mg/day and prednisone 1mg/kg per day (80mg) were
started with human factor VIII. Considering the good bio-
logical response, prednisone was decreased to 0.5mg/kg per
day after 2 weeks. Results of serum protein electrophoresis;
serologies for virus, including HIV, hepatitis virus, cytome-
galovirus, and Epstein-Barr virus; and rheumatologic tests,
including rheumatoid factor, antinuclear antibody, and
antineutrophil cytoplasmic antibodies, were unremarkable.
Complete examination revealed bilateral gynecomastia and
an upper left quadrant breast nodule of 2  3cm. The
gynecomastia had appeared after the initiation of spirono-
lactone, and had been known by the patient and his general
practitioner for 10 years or more. No physical examination
of the gynecomastia had been made previously. The mam-
mographic findings are shown in Fig. 1.
An ultrasound-guided needle-core biopsy was per-
formed on September 28. Histopathological analysis
showed invasive ductal carcinoma. Staging, including tho-
racic, abdominal, and pelvic computed tomography (CT)
scanning; bone scintigraphy; and laboratory parameters
(corrected calcemia, liver function tests) was unremarkable.
A mastectomy was performed on October 15, without com-
plication. At gross examination, the tumor measured 1.8cm.
Histologically, it was invasive ductal carcinoma with an in
situ ductal carcinoma component (Fig. 2a,b). The invasive
carcinoma was organized partly in tubes (50% of tumor
surface), nuclear pleomorphism was marked, and the mi-
totic count was low (six mitoses per ten high-power fields),
corresponding to histoprognostic grade II according to the
Elston and Ellis system. The in situ component accounted
for 10% of the tumor surface, was located within the tu-
moral nodule, and exhibited low nuclear grade and a cribri-
form pattern. All (100%) tumor cells, in both components,
expressed estrogen receptors (Fig. 2b) and progesterone
receptors. Peritumoral mammary tissue exhibited diffuse
Fig. 1. Mammography. Mass with irregular contours (diameter, 1.1 cm)
without calcifications, at the junction of the upper and the lower outer
left quadrant of the left breast
a
b
Fig. 2a,b. Invasive ductal carcinoma, histopathology. a Invasive ductal
carcinoma with minimal in situ component (right), and fibrotic
peritumoral mammary tissue consistent with the fibrous type of gy-
necomastia (left). b Immunohistochemical staining, showing that 100%
of the invasive carcinoma cells, as well as some normal duct epithelial
cells (top), express estrogen receptor. a H&E, 200; b immuno-
peroxidase, 400
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fibrosis surrounding ducts, without significant epithelial hy-
perplasia, consistent with the fibrous type of gynecomastia
(Fig. 2a). Two axillary sentinel lymph nodes were analyzed
on 12 sections 250µm-thick, after both hematoxylin eosin
and immunohistochemical stainings, the latter using an
antibody directed to cytokeratins. No tumor cells were
found by these procedures. The final pathological diagnosis
was invasive ductal carcinoma, grade II, pathological stage
pT1pN0 (sn). Spironolactone was stopped and adjuvant
tamoxifen started. The patient returned home on October
23. Blood test results rapidly returned to normal and the
immunosuppressive therapy was stopped after 7 months.
The factor VIII level was in the upper normal range and
factor VIII inhibitor was undetectable. After 2 years, the
patient remains clinically well, without clinical or biological
recurrence. At physical examination, the size of the right
gynecomastia has decreased and the consistency is more
adipose.
Discussion
Acquired hemophilia is a rare disease caused by the
development of auto-antibodies against factor VIII. In
approximately 50% of cases, the etiology is unknown.1
Autoimmune disorders account for more than 10% of
cases, paraneoplasic syndrome for 7%–15% of cases, the
third trimester of pregnancy or the postpartum period for
10% of cases, adverse drug reaction for 3%–6% of cases,
and various skin disorders for 2%–5% of cases.1 The treat-
ment of choice for acquired hemophilia includes the use of
human or porcine factor VIII in patients who are bleeding,
and immunosuppressive agents (corticosteroids with or
without cyclophosphamide or chlorambucil).4,5
We performed a Medline search of the literature and
a review of appropriate publications to identify a link
between acquired hemophilia and spironolactone or breast
carcinoma. No case of association between spironolactone
and acquired hemophilia was described. Adverse drug reac-
tions with penicillin, ampicillin, phenytoin, nitrofurazone,
chloramphenicol, sulfa drugs, or fluoroquinolones have
been associated with factor VIII inhibitors.1 Some case re-
ports have suggested a relationship between chronic renal
failure and acquired hemophilia.6 This association was not
described in the review by Bossi et al.1 In our patient, the
blood test results rapidly returned to norm after the immu-
nosuppressive therapy was started and the left mastectomy
performed. At the same time, the magnitude of chronic
renal failure did not change. For this reason, we have not
suggested a relationship between chronic renal failure and
acquired hemophilia. We identified only three other cases
describing an association between breast cancer and ac-
quired hemophilia.7–9 These three cases occurred in women.
In our patient, breast carcinoma was considered to be the
“primum movens”. A retrospective study of 41 patients
with cancer and acquired hemophilia revealed that in 61%
of cases solid-organ tumor was the underlying diagnosis.7
Prostate cancer was the most common, followed by lung
carcinoma. The most common histologic type was
adenocarcinoma.
Putative risk factors for breast carcinoma in men in-
cluded advanced age, Jewish ancestry, a positive family his-
tory, excess exposure to female hormones (Klinefelter’s
syndrome), environmental exposure (irradiation), alcohol,
and obesity.2,3 Our patient had none of these risk factors.
Considering the well-known causal relationship between
spironolactone and gynecomastia, although gynecomastia is
not recognized per se as a predisposing factor for breast
carcinoma, the question of a linkage between long-term
spironolactone therapy and breast carcinoma was raised
in this case. The manifestations of spironolactone’s
antiandrogenic effects are various and partly dose- and
time-dependent; in men, these involve gynecomastia, de-
clining libido, and impotence. Competitive antagonism on
androgenic tissue receptors by spironolactone is thought to
be the main mechanism. Weak inhibition of androgen syn-
thesis and increased conversion of androgens to estrogens
were irregularly demonstrated and are probably minor.10,11
Animal studies have shown an increased rate of neoplasia,
including breast carcinoma, in rats on high-dose
canrenoate, another aldosterone antagonist which shares a
common metabolite (canrenone) with spironolactone.12
Some cases of breast carcinoma in women under spirono-
lactone therapy have been reported, but this association
may only be fortuitous.13 Male cases have also been re-
ported to the WHO database, without a proven causal
relationship.
Although there is no proven association between
spironolactone and breast malignancy, a doubt cannot be
ruled out, considering the antiandrogenic characteristics of
spironolactone and animal data suggesting the oncogenic
potential of spironolactone’s metabolite. As spironolactone
is now widely used, especially for cardiac failure, special
attention should be paid to its safety profile.
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